Full-Time
Senior Quality Supervisor
Quality Control
Abbott
10,001+ employees
Global healthcare company manufacturing medical devices
Compensation Overview
$90k - $180k/yr
Pacoima, Los Angeles, CA, USA
In Person
On-site in Sylmar, CA with up to 10% travel.
Bachelor's
 Engineering Management (1) |
|---|
Get referred to Abbott
See people who can refer or advise you
- Bachelors Degree in Engineering / Business / Operations or an equivalent combination of education and work experience.
- Minimum 5 years of related work experience.
- Knowledge of applicable regulations and standards affecting the manufacture of Medical Devices (i.e., cGMPs and CFRs).
- Ability to lead and motivate people to ensure safety, quality and performance.
- Drive for Results: Collaboratively set realistic, challenging, measurable goals and timetables. Keep self and others focused on key performance indicators. Be willing to adjust goals to meet changing business needs. Set short-term objectives that drive toward longer-term goals or strategies. Monitor or adjust activities to meet objectives. Stay with a position or a plan of action until the desired objective is achieved. Support staff with the necessary resources to achieve goals. Hold self and others accountable for delivering high quality results. Regularly evaluate self and team on goal attainment, process used to achieve goals and competitive benchmarks
- Set Vision and Strategy: Understand trends, their implication and opportunities, in the global environment (customer, technical, health care, regulatory, etc.); Gather information from multiple sources including customers, peers, staff and external experts. Assess information with a global perspective, identifying opportunities and threats and developing long-term strategies to respond. Balance opportunities, resources and investments to maximize Abbott’s growth. Maintain a strong customer focus. Link the customer needs and market place conditions. Develop strategies that convert customer requirements into products and services. Identify and capitalize upon opportunities to create value from cross-division capabilities.
- Adaptability: Maintain effectiveness in continually changing work environment. Adjustquickly to work within new work structures, processes, requirements or cultures. Treatchange and new situations as opportunities for learning or growth. Speak positively aboutchange to others. Modify behavior to deal effectively with changes in the workenvironment. Try new approaches for new situations and respond to change usingeffective behaviors. Reprioritize to meet schedule demands. Confront and resolve conflict and lead efforts to resolve critical situations.
- Teamwork: Work effectively with others to accomplish a common goal. Maintain good working relationships and deal with conflict in a productive way. Provide feedback to others on the team and exhibit strong interpersonal / communication skills. Demonstrate leadership ability and a successful history of accomplishing tasks through the efforts of others. Provide clear direction while exercising good business judgment to support creative decisions in a fast paced environment that requires flexibility to respond to ongoing changes and challenges.
- Innovation: Generate innovative solutions in work situations; try different and novel ways to deal with work problems and opportunities. Identify alternative ways to view or definite problems. Use many diverse sources for ideas and inspiration. Target areas for innovation and consider many solutions.
- Responsible for implementing and maintaining effectiveness of the quality system by ensuring quality/compliance of manufacturing / production processes.
- Pro-actively seek ways to maintain and improve quality standards.
- Use objective and quantifiable measures to decrease safety incidents and to increase quality and performance.
- Promote a safe work environment by ensuring the highest standards in employee safety.
- Supervise, train, and develop nonexempt personnel.
- Develop goals / objectives for all assigned personnel. Monitor employees' performance against goals, provide performance feedback. Write and conduct development plans / performance appraisals. Manage employee HR issues.
- Manage and assign resources to address business needs, including staffing levels, overtime needs and project support.
- Provide leadership for the team and appropriately address quality, production and safety needs effectively.
- Be responsible for overall equipment performance & maintain equipment downtime to an acceptable level.
- Support equipment upgrades/new installations.
- Responsible for meeting daily production goals. Proactively seek ways to support the customer (i.e., working with engineering to find alternative resolutions that to issues, while maintaining compliance, without stopping production).
- Work as a liaison between functional departments to assist in resolving issues.
- Promote communication and teamwork across shifts /crews/sites as applicable.
- Provide support for compliance investigations. resolve corrective actions.
- Responsible for motivating all assigned personnel to ensure that all applicable documentation is within compliance of procedures and guidelines.
- Ensure all assigned personnel are in personal training compliance and unique training needs of the group are met.
- Participate in plant Safety, Quality and Operations meetings.
- Assist / support other functions as needed.
Abbott develops and sells medical technologies and health solutions across cardiovascular care, diabetes management, diagnostics, nutrition, and neuromodulation. Cardiovascular devices help manage heart health; diabetes products enable glucose monitoring; diagnostic tests provide timely results; nutrition products support health; neuromodulation therapies target the nervous system to relieve pain or aid movement. It differentiates itself with a broad, integrated portfolio and a focus on accessibility and affordability of technologies worldwide. Its goal is to improve global health and well-being by delivering life-changing technologies that are accessible and affordable.
Company Size
10,001+
Company Stage
IPO
Headquarters
Lake Bluff, Illinois
Founded
1888
Get referred to Abbott
See people who can refer or advise you
Simplify's Take
What believers are saying
- Google Health integration should widen Lingo adoption through consumer app distribution later in 2026.
- SimpleScreen CRC approval on July 27, 2026 unlocks Medicare coverage and Abbott’s U.S. sales push.
- M42 partnership in July 2026 expands Abbott’s early-cancer diagnostics footprint in the UAE.
What critics are saying
- FDA classified Libre 3 sensor issues as Class I recall on February 4, 2026.
- Abbott reported 860 serious injuries and seven deaths from falsely low Libre readings by January 7, 2026.
- Guardant Health’s FDA-approved Shield blood test directly challenges Abbott’s new colorectal screening launch.
What makes Abbott unique
- Abbott’s Lingo plus Google Health partnership, announced August 11, 2026, fuses CGM with AI coaching.
- Abbott commercializes Freenome’s SimpleScreen CRC in the U.S. this fall, expanding cancer screening.
- Abbott spans devices, diagnostics, nutrition, and diabetes, reducing dependence on any single product.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
401(k) Retirement Plan
401(k) Company Match
Flexible Work Hours
Remote Work Options
Paid Vacation
Paid Sick Leave
Paid Holidays
Professional Development Budget
Wellness Program
Growth & Insights and Company News
6 month growth
↑ 6%1 year growth
↑ 6%2 year growth
↑ 16%Abbott and Google Health have announced a multi-year partnership combining glucose monitoring with artificial intelligence to transform personal health management. The collaboration will integrate data from Abbott's Lingo continuous glucose monitor into the Google Health app, where AI-powered coaching will provide personalized recommendations on nutrition, activity, sleep and stress. The partnership includes a large-scale research study examining connections between glucose levels, wearable data and metabolic health. Lingo, Abbott's over-the-counter glucose monitor, targets adults not using insulin who want to understand how daily habits affect their glucose levels. Over 115 million American adults have prediabetes, with approximately 80% unaware of their condition. The companies aim to help people take proactive action before health challenges become chronic conditions. Lingo integrations will roll out in the Google Health app later this year.
Top 5 healthcare stocks to buy with $1000 in 2026. * August 8, 2026 Table of contents hide. Discover more Company News Pharmaceuticals 5. Abbott Laboratories (NYSE:ABT). Abbott Laboratories (NYSE: ABT) moves into the top five as one of the most diversified healthcare companies in the ranking. Instead of relying primarily on prescription medicines, Abbott Laboratories (NYSE: ABT) operates across medical devices, diagnostics, nutrition and branded generic pharmaceuticals. That broad mix gives the company exposure to everyday healthcare needs as well as some of the industry's fastest-growing technologies. Its recognizable products demonstrate just how diverse the business has become. Similac gives Abbott Laboratories (NYSE: ABT) exposure to nutritional products. Alinity diagnostic systems serve laboratories and healthcare providers. FreeStyle Libre has established the company as a major competitor in continuous glucose monitoring, one of the fastest-changing markets in diabetes care. FreeStyle Libre is particularly important to the growth thesis. Continuous glucose monitoring allows people with diabetes to monitor glucose levels without relying exclusively on repeated traditional finger-stick testing. As these systems have become smaller, easier to use and more widely adopted, the market has expanded rapidly. CFRA analyst Sel Hardy anticipates strong demand for FreeStyle Libre 3, reinforcing the argument that Abbott Laboratories (NYSE: ABT) can generate meaningful organic growth from medical technology even while maintaining exposure to more defensive healthcare categories. The company is also moving more aggressively into cancer screening through its acquisition of Exact Sciences. Cancer diagnostics represent a major healthcare opportunity because earlier detection can dramatically influence treatment decisions and patient outcomes. Expanding into this market gives Abbott Laboratories (NYSE: ABT) another potential long-term growth engine while complementing its existing diagnostic capabilities. Discover more Investment Drugs & Medications Hardy also highlights the company's strong balance sheet, innovative portfolio and record of consistent dividend growth. Those characteristics can make Abbott Laboratories (NYSE: ABT) particularly attractive to investors who want healthcare exposure without depending completely on speculative drug pipelines. CFRA assigns Abbott Laboratories (NYSE: ABT) a "buy" rating and a $120 price target, compared with a July 30 closing price of $105.61. That represents approximately 14% potential upside based on the supplied figures. The broader investment case goes beyond a single analyst target. Healthcare is moving increasingly toward continuous monitoring, early detection and data-driven medicine. Abbott Laboratories (NYSE: ABT) participates in all three areas through glucose monitoring and diagnostics while retaining businesses in nutrition and other essential healthcare categories. That combination helps explain why Abbott Laboratories (NYSE: ABT) deserves consideration among the best healthcare stocks to buy for long-term investors. It is not dependent on one miracle drug or one clinical trial. Instead, the company has assembled a collection of businesses that benefit from some of the healthcare industry's most durable trends.
Senseonics' in-house distribution bet pays off with record revenue, profitability still distant. Record CGM sales drive Senseonics' revenue, but the path to profitability remains unclear. Omar Ford, Editor-in-Chief, MD+DI, Informa Markets - Engineering August 7, 2026 At a glance. * Senseonics reported 2Q26 revenue of $14.5 million, beating expectations. * Net loss widened to $36.7 million from $14.5 million year-over-year. * Senseonics resumed direct distribution of its CGM products a year ago. Senseonics Holdings is seeing strong earnings growth from distributing its diabetes products and year-long continuous glucose monitor (CGM). The Germantown, MD-based company reported 2Q26 revenue of $14.5 million, beating the consensus of $13.4 million. BTIG analysts said that revenue grew more than 150%, representing the "highest quarterly shipment volume in company history." Senseonics momentum surge can be traced back a year ago when it announced it would resume direct distribution of the Eversense CGM products. Ascensia Diabetes Care, a Basel, Switzerland-based company, held the exclusive worldwide distribution rights for the Eversense CGMs since 2020. Senseonics President, CEO and Director Tim Goodnow said, "Coming into the year, our thesis was that bringing the commercial organization fully in-house, combined with the strength of Eversense 365, would unlock durable revenue growth and margin expansion," according to a Seeking Alpha transcript of the call. "And so far, we see this thesis is playing out ahead of expectations." In response to the strong earnings, Senseonics raised 2026 full-year revenue guidance to $62 million to $66 million. Previous guidance was set at $60 million to $64 million. Redefining CGM in a competitive market. Part of the company's plan to redefine CGMs for users came in September of 2014 when Senseonics won FDA clearance for Eversense 365, a year-long CGM system. The clearance came during a time when the CGM market was teeming with innovation. At the time, Medtronic and Abbott had announced a collaboration to develop an integrated continuous glucose monitoring system (CGM) based on the FreeStyle Libre technology. Abbott remained busy - and secured a nod from FDA for an over-the-counter CGM. Dexcom would obtain FDA clearance for an OTC CGM, too. However, Senseonics touted Eversense 365 as the first year-long CGM system, designed to minimize the frequency of sensor replacements and provide consistent, long-term glucose monitoring. "We're redefining what a CGM can be for people with diabetes," Goodnow said, according to a Seeking Alpha transcript of the earnings call. The march toward profitability. Despite growth in revenue, the company's net loss grew from $14.5 million in the prior year period to about $36.7 million in 2Q26. The increase in loss was chalked up to increased SG&A and R&D expenses. The firm also has high operating expenses, which range from $150 to $160 million for a year, which, according to an article from GuruFocus, "suggests the company is still in a heavy investment phase with no near-term profitability." BTIG Analyst Marie Thibault wrote, "We continue to be encouraged by the positive commercial momentum from Eversense 365 and the company's ability to consistently beat and raise, though we continue to await further clarity on the eventual path to profitability." Editor-in-Chief, MD+DI, Informa Markets - Engineering Omar Ford is a seasoned journalist specializing in medical technology, healthcare innovation, and the medical device and diagnostics industry. As the editor-in-chief of Medical Device + Diagnostics Industry (MD+DI), he has earned a reputation as a leading authority in the field, offering in-depth insights into the latest trends, regulatory changes, and technological advancements shaping the future of healthcare. Omar has been a featured speaker at MD&M and MEDevice events. Omar has written for several publications prior to MD+DI. He is a former contributor at Bioworld Medtech, an online publication owned by Clarivate. He was a general assignment reporter for the Beaufort Gazette and an education and county reporter for the Griffin Daily News. He is the 2001 winner of the Judson Chapman Award from the South Carolina Press Association and the 2003 McClatchy President's Award recipient. Omar has a bachelor's degree in print journalism from the University of South Carolina. Throughout his tenure at MD+DI, Omar has covered a wide array of topics, including medical technology innovations, regulatory affairs, market dynamics, and the growing impact of artificial intelligence in healthcare. Omar is the host of the Let's Talk Medtech podcast. Want more MD+DI in your search results?
Amani Aljuaid: driving Human Capital Strategy and Organizational Transformation at Siemens Healthineers Saudi Arabia. Strong organizations are built on more than products, services or technology; they are built on people. Behind every successful business transformation is a leadership team capable of aligning talent, culture and strategy to deliver sustainable growth. At Siemens Healthineers Saudi Arabia, Amani Aljuaid is helping shape that future through a people-first approach to leadership, organizational development and workforce transformation. As Country Head of HR, Aljuaid leads the company's human resources strategy across Saudi Arabia, supporting Siemens Healthineers' mission to advance healthcare and improve patient outcomes. Her responsibilities span the full employee lifecycle, from workforce planning and leadership development to organizational transformation, performance management, talent acquisition and employee engagement. Working across both the company's in vivo and in vitro business lines, she partners closely with executive leadership to ensure people strategies directly support business priorities while remaining aligned with Saudi Arabia's Vision 2030 ambitions, Saudization initiatives and global corporate standards. Building organizations through strategic HR leadership. With more than 14 years of experience across American, Norwegian and German multinational organizations, Aljuaid has established herself as a strategic HR leader with expertise in navigating complex organizational change. Her leadership extends well beyond traditional human resources management. Throughout her career, she has led localization initiatives, organizational redesign projects, leadership capability development, culture transformation programmes and business expansion strategies, helping organizations adapt to changing market environments while strengthening employee experience and organizational performance. Her work is centred on connecting people with purpose - ensuring that business strategy, leadership capability and workplace culture evolve together to create resilient, future-ready organizations. Leading transformation across global healthcare organizations. Before joining Siemens Healthineers, Aljuaid spent more than eight years at Abbott, progressing through a series of increasingly senior leadership positions. She most recently served as Human Resources Director, where she led strategic HR transformation initiatives while partnering with executive leadership to strengthen organizational effectiveness, succession planning, workforce capability and employee engagement. Prior to that, she served as Head of Human Resources, where she established the company's HR function from the ground up, developing end-to-end people processes, organizational policies and talent strategies that supported long-term business growth. Earlier roles as Talent Acquisition Manager and Senior Talent Acquisition Specialist further strengthened her expertise in executive hiring, workforce planning, employer branding and talent management. Her career also includes nearly four years with Jotun, where she gained experience across both human resources and commercial operations, providing a broad understanding of organizational performance from multiple business perspectives. Developing future-ready organizations. Throughout her career, Aljuaid has championed initiatives that strengthen leadership capability, improve employee experience and foster inclusive workplace cultures. Her expertise spans: * Human Capital Strategy * Organizational Development * Leadership Development * Talent Acquisition & Succession Planning * Workforce Planning * Organizational Transformation * Change Management * Employee Engagement * Diversity & Inclusion * Performance Management * HR Governance * Strategic Business Partnership By combining international HR best practices with a deep understanding of Saudi Arabia's evolving business landscape, she continues to help organizations develop agile workforces capable of supporting long-term growth. Academic foundation and executive development. Aljuaid holds a Master of Business Administration (MBA) in Human Resources from the University of Business & Technology, following a Bachelor's degree in International Business from King Abdulaziz University. She has also completed the Women Leaders Program at INSEAD, further strengthening her executive leadership capabilities in strategic planning, organizational leadership, influence and change management. Her continued investment in executive education reflects her commitment to building high-performing organizations through thoughtful leadership and people development. Shaping the future of HR leadership. As Saudi Arabia continues investing in healthcare innovation, workforce localization and economic diversification under Vision 2030, strategic HR leadership has become increasingly important in helping organizations navigate change while attracting, developing and retaining exceptional talent. Through her work at Siemens Healthineers, Amani Aljuaid continues to demonstrate how human capital strategy can become a competitive advantage - creating workplaces where business transformation and employee success grow together.
FDA approves SimpleScreen(TM) CRC blood test for colorectal cancer screening in average-risk adults. The approval provides adults aged 45 years and older at average risk of colorectal cancer with an additional blood-based screening option, expanding access for individuals who are overdue for screening. The US Food and Drug Administration (FDA) has approved SimpleScreen(TM) CRC, Freenome's blood-based colorectal cancer screening test, for adults aged 45 years and older who are at average risk of the disease, marking the company's first commercial product. The approval expands the range of screening options available for eligible patients and may help increase screening uptake among individuals who are reluctant to undergo stool-based testing or colonoscopy, while not replacing established diagnostic pathways. | Field | Content | | Alert Type | Drug Approval | | Drug Name | SimpleScreen(TM) CRC | | Indication | Blood-based screening for colorectal cancer in adults aged 45 years and older who are at average risk of colorectal cancer. | | Therapy Area(s) | Oncology; Gastroenterology | | Geography | US (FDA) | | What Happened | The FDA approved SimpleScreen(TM) CRC on 27 July 2026 for colorectal cancer screening in adults aged 45 years and older who are at average risk of the disease. The approval gives Freenome its first FDA-approved commercial product and authorises Abbott, which holds exclusive US commercialisation rights, to launch the blood-based screening test in the US. The approval expands the range of FDA-authorised blood-based colorectal cancer screening options available for average-risk adults. | | Why It Matters | The approval provides clinicians and eligible patients with an additional non-invasive colorectal cancer screening option. While blood-based testing does not replace colonoscopy or other recommended diagnostic pathways, it may improve participation among people who remain unscreened, helping to broaden access to recommended colorectal cancer screening. | | Supporting Context | Colorectal cancer is the second leading cause of cancer-related death in the United States. Freenome estimates that up to 60 million eligible Americans are overdue for colorectal cancer screening, highlighting the need for additional screening options. | | Key Takeaway | FDA approval of SimpleScreen(TM) CRC expands the range of blood-based colorectal cancer screening options available for average-risk adults aged 45 years and older. | | What to Watch | Abbott plans to commercially launch SimpleScreen(TM) CRC in the United States during autumn 2026. Uptake, reimbursement and future updates to clinical screening recommendations will be important to monitor. | | Primary Source | https://investors.freenome.com/news-releases/news-release-details/fda-approves-freenomes-simplescreentm-crc-blood-based-screening | | Relevant Date | 27 July 2026 | Discover how nuaxia can support your next medical education initiative: